Subsequent cell–cell fusion assays found that the COVID-19-associated PLSCR1(H262Y) mutant did not inhibit membrane fusion despite retaining lipid scramblase activity (Fig. 4j). The gene discussed is PLSCR1; the disease is COVID-19.